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Virus-like glycodendrinanoparticles displaying
quasi-equivalent nested polyvalency upon
glycoprotein platforms potently block viral infection
Renato Ribeiro-Viana1,2, Macarena Sánchez-Navarro1, Joanna Luczkowiak3, Julia R. Koeppe1,
Rafael Delgado3, Javier Rojo2 & Benjamin G. Davis1
Ligand polyvalency is a powerful modulator of protein–receptor interactions. Host–pathogen
infection interactions are often mediated by glycan ligand–protein interactions, yet its
interrogation with very high copy number ligands has been limited to heterogenous systems.
Here we report that through the use of nested layers of multivalency we are able to assemble
the most highly valent glycodendrimeric constructs yet seen (bearing up to 1,620 glycans).
These constructs are pure and well-defined single entities that at diameters of up to 32 nm
are capable of mimicking pathogens both in size and in their highly glycosylated surfaces.
Through this mimicry these glyco-dendri-protein-nano-particles are capable of blocking (at
picomolar concentrations) a model of the infection of T-lymphocytes and human dendritic
cells by Ebola virus. The high associated polyvalency effects (b4106, b/N B102–103) dis-
played on an unprecedented surface area by precise clusters suggest a general strategy for
modulation of such interactions.
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T
he initial stages of an infectious process are crucial for
subsequent immune response and elimination of patho-
gens1. The innate immune system comprises mechanisms
and specialized cells responsible for first contact with external
biological agents2. Detection of invaders via pathogen recognition
receptors and subsequent activation of antimicrobial defences
triggers specific antigen responses3. DC-SIGN (dendritic cell-
specific intercellular adhesion molecule-3-grabbing nonintegrin)
receptor is one of the most important pathogen recognition
receptor. It is expressed mainly on the surface of dendritic
cells (DCs), and some subtypes of macrophages4. DC-SIGN
recognizes in a multivalent manner mannose and fucose
containing glycoproteins5, such as ICAM-3 (intercellular
adhesion molecule 3) present in T cells, and envelope
glycoproteins found on pathogens6. By using DC-SIGN as an
entry point some viruses are capable of escaping from the
processing and degradation events carried out by the immune
defence machinery at antigen-presenting cells7. Therefore,
the inhibition of pathogen entry through the blockade of this
receptor at early stages of infection is one strategy for new
antiviral agents.
Several studies have been directed towards the preparation of
synthetic carbohydrate systems able to block or stimulate DC-
SIGN8–21. Despite their elegant design, one of the problems that
these artificial systems face is achieving adequate size and
multivalency to sufficiently mimic natural systems such as viruses
or other pathogens while maintaining full control of shape and
structure16. Indeed, ligand valencies beyond 32 (refs 9,18) have not
been possible before with full control (Indeed, valencies 4100 are
rare in any glycodendrimeric structure. See the following references
André et al.22 and Camponovo et al.23 for examples of 128-mer
lactoside and 243-mer xyloside display, respectively.)22,23.
We have previously demonstrated that symmetrically multi-
valent glycan ligands mounted on protein platforms (glycoden-
driproteins) are useful tools to study carbohydrate–protein
interactions and are able to control or modulate a desired
response24–27. Other dendrimeric displays on proteins have also
been explored subsequently28–30. However, to date, this approach
has provided only limited carbohydrate valency levels on single
protein platforms. We envisaged that a controlled design for a
highly polyvalent protein display of sugars might be achieved
through a novel strategy of ‘nested polyvalency’ (polyvalent
display of polyvalency) (Fig. 1a).
We describe here the realization of this approach through the
multivalent assembly of protein monomers themselves carrying
polyvalent glycan display motifs (glycodendrons). The resulting
glycodendriprotein homomultimers display many glycans in a
precise manner. Consistent with associated guiding physical
principles31–33, these constructs therefore display symmetry and
pseudosymmetry at both the level of protein assembly and
glycodendron. These synthetic glycoprotein assemblies display
the highest known number of glycans (n¼ 1,620) yet presented in
a homogeneous manner. We have applied this idea (Fig. 1) here
to the inhibitory immunomodulation of a DC-SIGN-pathogen
glycoprotein interaction (Fig. 1b).
Results
Construction of glyco-dendri-protein-nano-particles. We rea-
soned that assembly of an entity with similar dimensions (in the
form of a self-assembled protein sphere-like icosahedron Qb34,
B28 nm in diameter) might mimic the display in target
pathogens (Ebola pseudotyped virus particles have B90 nm in
diameter). Using a tag-and-modify27 strategy, we chose to
selectively introduce a non-natural amino acid (tag) on the
protein that could be used for the attachment (modify) of the
selected glycodendrons appropriately functionalized at the focal
position. As a stringent test of this approach we chose to mimic the
highly glycosylated pathogen envelopes of Ebola virus. We selected
a monomer Qb34,35 protein as carrier, which assembles into a 180-
copy multimer. Qb multimer has been used by us and others to
display glycans for other purposes but in these prior experiments
only partial levels of nonspecific modification were achieved (see
Supplementary Discussion). The result of these prior incomplete
reactions was a formation of mixtures and not the desired
homogeneous and (pseudo)symmetrical display required for this
study36,37. This proteic platform provided the necessary viral mimic
scaffold (core diameter, B28 nm)34 to construct the desired
multivalent systems.
The designed glycodendrons were prepared in a straightforward
manner by the Cu(I)-catalysed modification38,39 of the Huisgen
cycloaddition as depicted in Fig. 2. a-D-Mannose was chosen to be
introduced onto the dendritic scaffolds as a relevant ligand that is
recognized by DC-SIGN5. Synthesis of glycodendron 4 was
accomplished using a modular strategy that advantageously
avoided the need for carbohydrate protection. First, unprotected
azidoethyl mannoside 3 (see Supplementary Methods)8 was
coupled to the trialkynyl pentaerythritol core 2 using CuSO4 and
sodium ascorbate in a 1:1 mixture of water:THF (tetrahydrofuran)
at room temperature (RT)40. The focal azido group required for
subsequent site-specific conjugation to the protein tag, was
introduced by reaction with sodium azide to give 5. The designed
modular strategy also allowed use of 5 in the construction of higher
generation glycodendron 8. Thus, coupling of 5 with the trialkynyl
core 6 gave 7 (Fig. 2), which was similarly converted to an azide 8
for protein modification.
Unnatural alkyne-containing amino acid L-homopro-
pargylglycine (Hpg) was site-specifically introduced into the
protein that would make up the proteic scaffold (Qb) to serve as
an alkyne ‘tag’ through the expression of corresponding gene
sequences in an auxotrophic strain of E. coli (B834(DE3))41. Gene
sequences were designed to create a protein displaying alkyne at a
site on the outer surface of the eventual icosahedral platform
(Hpg16) for which the position could simply be controlled by the
‘Met’ triplet codon ATG. Replacement of wildtype methionine
(Met) residues, with near-isosteric amino acid isoleucine allows
reassignment of the codons in the gene sequence to allow
incorporation instead of Hpg as a ‘tag’ (see Supplementary
Methods for full details). The resulting Qb-(Hpg16)180 was
characterized, including by mass spectrometry and dynamic light
scattering (Fig. 3 and see Supplementary Methods and
Supplementary Fig. S1), demonstrating the introduction of the
Hpg amino acid into the sequence. On the basis of previous
results42,43, Qb-(Hpg16)180 was modified using a reaction mixture
of Cu(I)Br complexed by tris[(1-ethylacetate-1H-1,2,3-triazol-4-yl)
methyl]amine in acetonitrile (Fig. 3a). It should be noted that the
presence of Hpg on the protein results in slower Huisgen
cycloaddition reaction rates in comparison with those obtained
when azide in the form of azidohomoalanine (Aha) is present in the
protein42,43. Optimization of the reaction conditions by varying
catalyst loading and stepwise addition, afforded the desired
glycodendron-bearing virus-like particles. Thus, reaction of Qb-
(Hpg16)180 with trivalent glycodendron 5 afforded Qb-(Man3)180
bearing 540 terminal mannosyl residues and reaction with second-
generation nonavalent glycodendron 8 gave Qb -(Man9)180. Both
reactions proceeded with 495% conversion; consistent with greater
bulk a longer reaction time (up to 7.5 h) was required for reaction
of 8 to form 1,620-mer Qb- (Man9)180. Increasing particle diameter
was observed, Qb (27.6 nm)-Qb-(Man3)180 (29.8)-Qb-
(Man9)180 (32.0), consistent with the controlled introduction of
‘shells’ of glycosylation B1.1 nm thick (Fig. 3b and see
Supplementary Table S1 for rough estimate of dendron length)
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for each dendron generation. To the best of our knowledge,
this is the first synthesis reported of such highly functionalized
monodisperse glycodendriproteins (bearing up to 1,620 terminal
sugar moieties) using a convergent approach.
Inhibition of DC-SIGN in vitro and on T lymphocytes. The
inhibitory function of these glycodendriprotein particles was
tested in several ways. Competition ELISA assay (See
Supplementary Methods and Supplementary Figs S2 and S3)
revealed that Qb-(Man3)180 could completely inhibit the binding
of DC-SIGN (as an Fc chimera) to a synthetically mannosylated
glycoprotein (albumin bearing Mana1–3(Mana1–6)Man) with an
estimated IC50 B35–40 nM. A complete lack of inhibition by
control, non-glycosylated Qb confirmed dependence of this
promisingly potent inhibition upon glycan.
Next, an Ebola viral infection model44, was explored using
mammalian T-lymphocyte (Jurkat) cells displaying DC-SIGN.
Recombinant viruses were produced in HEK 293 T cells; the viral
construction was pseudotyped with Ebola virus envelope GP
(EboGP) or the vesicular stomatitis virus envelope glycoprotein
(VSV-G) and expressed luciferase as a reporter of the infection45.
The inhibition of DC-SIGN-dependent infection of T-lymphocyte
Jurkat cells (examined in at least three independent experiments)
demonstrated that unglycosylated Qb reduced infection minimally
(Fig. 4a). In contrast, Qb-(Man3)180 and Qb-(Man9)180 showed
strong dose-dependent inhibition of the infection process (Fig. 4a–
c). Indeed, Qb-(Man9)180 presented a notable antiviral activity,
inhibiting infection by B80% at 5 nM; estimated IC50s¼ 9.62 nM
for b-(Man3)180 and¼ 910 pM for Qb-(Man9)180.
VSV-G is able to infect T-lymphocyte Jurkat cells
independently of DC-SIGN44 and provided a positive control in
infection experiments; consistent with the proposed model of
inhibition (Fig. 1) this glycan-independent pathway for VSV-G
was completely uninhibited (Fig. 4b,c). In this model, the Ebola
infection process is absolutely dependent on the presence of DC-
SIGN on the cell surface. Jurkat cells not expressing DC-SIGN
were used as a negative control in the infection studies and
showed no infection by Ebola pseudovirus (See Supplementary
Fig. S4). The ratio of infection in cis between Jurkat DC-SIGNþ
and Jurkat cells was B2,600 for Ebola virus infection and 0.96 for
VSV infection.
Blocking of DC infection by pseudotyped Ebola. Having shown
such potent inhibition of infection of a stable cell line that dis-
plays DC-SIGN, we next evaluated inhibition in the perhaps more
relevant and more demanding context of inhibition of primary
cells. DCs are a primary target of Ebola infection; these display
multiple C-type lectins that could provide a different or modu-
lated route for infection with potentially higher affinty for virus.
Accordingly, DCs were generated from isolated human peripheral
blood mononuclear cells (PBMCs) and tested. We were pleased to
find that as for the stable Jurkat cell line presenting DC-SIGN
alone, Qb-(Man9)180 displayed potent activity (Fig. 4d), inhibiting
infection by 480% at 5 nM and 495% at 25 nM (estimated IC50
B2 nM for Qb-(Man9)180). Excitingly, these data indicate that the
mode of inhibition of these synthetic glycodendrinanoparticles
translates into cellular contexts relevant to human infection and
are consistent with the mode of action suggested in Fig. 1.
Discussion
Although the evaluation of the number of monomer units
interacting during these inhibitory processes is complicated by
quasi-equivalence32, the data obtained indicate that these systems
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Figure 1 | Schematic representation of the nested polyvalency strategy. (a) Nested symmetrical assembly of virus-like glycodendrinanoparticles using a
tag-and-modify strategy. Glycodendrons are created through iterative multivalent assembly and then attached to multiple tags, each in a monomer protein.
(b) Ebola (shown in red) infection model and its competitive inhibition with virus-like glycodendrinanoparticles.
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Figure 2 | Creation of polyvalent mannose-terminated glycodendrons. Synthesis of the glycondendron reagents 5 and 8 used in the assembly of virus-like
glycodendri-nano-particles (see Fig. 3). TBTA, tribenzyl(tris)triazoylamine; DMF, N,N-dimethylformamide.
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monomer methyl a-D-mannopyranoside) (see Supplementary
Table S2). The inhibitory properties of each mannoside monomer
unit can therefore be considered46 to be B250-fold and B860-
fold (as judged by b/N, see Supplementary Table S2) more potent
when displayed in Qb(Man3)180 and Qb-(Man9)180, respectively,










































































































Figure 3 | Controlled assembly and characterization of virus-like glycodendri-nano-particles. (a) A tag-and-modify strategy allowed the generation of
the second nested layer of multivalency from Qb-(Hpg16)180 using glycondendron reagents 5 and 8. R¼ corresponding glycodendron. (b) Dynamic light
scattering histograms showing the hydrodynamic radius of Qb (radius 13.8 nm), Qb-(Man3)180 (radius 14.9) and Qb-(Man9)180 (radius 16.0). (c) Mass
spectrometric analysis of monomer proteins of the particles. Pi, phosphate.
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relies upon a vital combination of not only a high number of
displayed ligands but also display size and geometry. To date, no
homogeneous polyvalent systems have been described that can
generate such a large surface area (solvent-accessible surface area
B725,000 Å247) as the systems we have described here. The
system we describe here is based on an icosahedral scaffold
(T¼ 3, triakis iscosahedral) that generates several underlying
quasi-symmetry elements including those that relate the
displayed glycodendrons in a two-fold, three-fold and six-fold
manner (see Supplementary Movie 1). It is tempting to speculate
that this, in turn, allows the simultaneous display of many distinct
putative global glycan clusters where the glycan ‘tips’ are also
quasi-equivalent (for example, 6-fold-related faces displaying a
resultant 54-mer in Qb-(Man9)180 or a 3-fold-related 9-mer in
Qb-(Man3)180, see Supplementary Movie 1). In this way, the
nested glycan polyvalency that we have developed here may allow
many subtly varying polyvalent combinations to be displayed,
each of which (or even a combination of which) might give rise to
optimal biological function (here inhibition of Ebola binding).
These constructs are therefore not ‘balls of sugar’ but
homogenous constructs that array varying faces with different
polyvalent glycan arrangements. Thus, their most relevant
structural features may well not be simply their average glycan-
to-glycan distance (as estimated, say, from Ca-to-Ca residue
distances of B28–40 Å for 2-fold up to 6-fold quasi-symmetry)
but instead the specific topology of glycan display and how that
relates to both the inter-domain distances in the DC-SIGN
tetramer48 as well as its organization on cell surfaces.49 Moreover,
initial inspection of other viral surfaces suggests that such
topologies might effectively out-compete not only Ebola but also
other human pathogens. The striking b values that we have
discovered here may well arise from such specific ‘optimal’ faces
(see Supplementary Movie 1 for illustrative examples of these
quasi-symmetrical faces). Indeed, although direct comparison
with non-viral systems is not possible, non-viral particles
displaying multiple mannosyl residues in a less ordered manner
are notably less potent and show much lower multivalency effects
(br20, see Supplementary Table S2).
In summary, a novel nested polyvalency approach combined
with tag-and-modify site-selective protein synthesis has allowed
the creation of homogeneous protein platforms bearing glyco-
dendrons. These well-defined polyvalent glycoprotein assemblies
present on their surface up to 1,620 copies of glycan, a remarkably
high valency never obtained before using a fully controlled
strategy. These glycodendriprotein particles show exciting anti-
viral activity, preventing mammalian cell infection by Ebola
pseudotyped virus through competitive blockade of the DC-SIGN
receptor in the nanomolar to picomolar range. These results
clearly indicate the efficiency of these systems to interact with this
pattern recognition receptor and to compete with pathogens
during their entry into target cells. Their in vivo activity remains
to be tested and it is possible that such constructs, if used in this
context, could elicit humoral responses that might potentially
neutralize some of the interactions studied here. The high activity
and fascinating (quasi)symmetric, high surface area morphology
of these new glycoconjugates provides promising candidates for







































































Figure 4 | Inhibition of viral infection of mammalian cells. (a) Comparison of infection rates of T-lymphocyte (Jurkat) cells displaying DC-SIGN by EboGP
pseudovirus in the presence of Qb, Qb-(Man3)180, Qb-(Man9)180; (b) Inhibition by Qb-(Man3)180 of EBOV-GP (EboG) pseudovirus and vesicular stomatitis
psuedovirus (VSV-G) in the infection (% infection)of T-lymphocyte (Jurkat) cells displaying DC-SIGN; (c) as for (b) using Qb-(Man9)180. Values correspond
to means of three experiments with s.e.m. shown; the IC50s were estimated using Graphpad Prism v4.0 at 95% with a 95% confidence interval (4.43–
20.9 nM for Qb-(Man3)180 and 651 pM–1.3 nM for Qb-(Man9)180) and settings for normalized dose-response curves. See the Supplementary Fig. S5 for
duplicated inhibition assays. (d) Inhibition of infection in cis of human DCs by EBOV-GP (EboG) using Qb-(Man9)180. Anti-DC-SIGN Ab is an antibody that
blocks DC-SIGN. Immature DCs were generated from isolated human PBMCs. Blockade with anti-DC-sign antibody was used as a positive control.
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Methods
Synthesis of glycodendrons. Glycodendron 4: 2-Azidoethyl a-D-mannopyrano-
side (306 mg, 1.2 mmol), 2-(2-chloroethoxy)ethoxymethyl trikis(2-propynylox-
ymethyl)methane (128 mg. 0.37 mmol), CuSO4  5H2O (9 mg, 0.04 mmol),
tribenzyl(tris)triazoylamine (39 mg, 0.07 mmol) and sodium ascorbate (29 mg,
0.15 mmol) were dissolved in 2 ml of THF/H2O (1:1). After consumption of the
starting material (3 h), the solvent was evaporated and the crude was purified by
size-exclusion chromatography (Sephadex LH-20 MeOH 100%), furnishing the
glycondendron 4 as a white foam (347 mg, 86%).
Glycodendron 5: Glycodendron 4 (80 mg, 0.07 mmol) and sodium azide (47 mg,
0.7 mmol) were dissolved in N,N-dimethylformamide (2 ml). The mixture was stirred
at 60 1C for 4 days. After consumption of the starting material, the solvent was
concentrated and the crude was purified by size-exclusion chromatography (Sephadex
G-25 H2O/MeOH 9:1), furnishing glycondendron 5 (76 mg, 95%) as a white foam.
Glycodendron 7: Glycodendron 5 (30 mg, 0.03 mmol), [2-[2-(2-chloroethox-
y)ethoxy]ethoxy]ethoxymethyl tris(2-propynyloxymethyl)methane (3.6 mg,
0.008 mmol), CuSO4  5H2O (0.5 mg, 0.002 mmol), tribenzyl(tris)triazoylamine
(1.7 mg, 0.003 mmol) and sodium ascorbate (1.3 mg, 0.006 mmol) were dissolved in
THF/H2O (1:1, 1 ml). After consumption of the starting material, the solvent was
evaporated and the crude was purified by size-exclusion chromatography (Sephadex
LH-20 MeOH 100%), furnishing glycondendron 7 (22 mg, 75%) as a white foam.
Glycodendron 8: Glycodendron 7 (25 mg, 0.007 mmol) and sodium azide (4 mg,
0.07 mmol) were dissolved in N,N-dimethylformamide (1 ml). The mixture was
stirred at 60 1C for 4 days. After that, the solvent was concentrated and the crude was
purified by size-exclusion chromatography (Sephadex G-25 H2O/MeOH 9:1), fur-
nishing glycondendron 8 (20 mg, 80%) as a white foam.
Synthesis of virus-like glycodendrinanoparticles. Glycoprotein Qb-(Man3)180:
Glycodendron 5 (2.84 mg, 0.002 mmol) was dissolved in sodium phosphate buffer
(50 mM, pH¼ 8, 200ml). Protein solution (180 mg, 100ml) was added to the above
solution and mixed thoroughly. A freshly prepared solution of copper (I) bromide
(99.999%) in acetonitrile (32.6 ml of 10 mg ml 1) was premixed with an acetonitrile
solution of tris[(1-ethylacetate-1H-1,2,3- triazol-4-yl)methyl] amine (12.6 ml of
100 mg ml 1). The preformed Cu-complex solution (25 ml) was added to the
mixture and the reaction was agitated on a rotator for at RT. After 4 h, 150 ml of
buffer and 50ml of fresh Cu-complex solution were added to the mixture again and
the reaction was agitated for a further 1.5 h. The resulting mixture was purified in
PD-MiniTrap (G-25) twice and concentrated on a vivaspin membrane con-
centrator (30 KDa molecular weight cut off) to 400 ml. To a virus-like particle
aliquot (20ml) was added 1 ml of TCEP (1 M) to allow the protein to denature
before analysis by liquid chromatography–mass spectrometry. Electrospray Ioni-
zation Mass Spectrometry (TOF ESþ ) (m/z): calc. 15,215; found 15,216.
Glycoprotein Qb-(Man9)180: Glycodendron 8 (4.8 mg, 0.001 mmol) was dissolved
in sodium phosphate buffer (50 mM, pH¼ 8, 50ml). Protein solution (90mg, 50ml)
was added to the above solution and mixed thoroughly. A freshly prepared solution
of copper (I) bromide (99.999%) in acetonitrile (32.6 ml of 10 mg ml 1) was pre-
mixed with an acetonitrile solution tris[(1-ethylacetate-1H-1,2,3- triazol-4-yl)me-
thyl] amine, (12.6 ml of 100 mg ml 1). The preformed Cu-complex solution (25ml)
was added to the mixture and the reaction was agitated on a rotator at RT. After 3
and 6 h, 50 ml of buffer and 12.5 ml of fresh Cu-complex solution were added to the
mixture again (each time) and the reaction was agitated for further 1.5 h. The
resulting mixture was purified in PD-MiniTrap (G-25) twice and concentrated on a
vivaspin membrane concentrator (30 KDa molecular weight cut off) to 400 ml. To a
virus-like particle aliquot (20ml) was added 1 ml of TCEP (1M) to allow the protein
to denature before analysis by liquid chromatography–mass spectrometry. ESI-MS
(TOF ESþ ) (m/z): calc. 17,889; found 17,893.
Production of recombinant viruses. Recombinant viruses were produced in 293T
cells. The viral construction was pseudotyped with EboGP or VSV-G and expressed
luciferase as a reporter of the infection45. One day (18–24 h) before transfection,
6 106 293T were seeded onto 10 cm plates. Cells were cultured in DMEM medium
supplemented with 10% heat-inactivated FBS, 25 mg gentamycin, 2 mM L-glutamine.
A few minutes before transfection, the medium on transfection plates was changed to
9 ml DMEM and chloroquine was added to 25mM final concentration. Transfection
reaction with all reagents at RT was prepared in 15 ml tubes: 183ml of 2M CaCl2,
450 ng of Ebola virus envelope, 21mg of pNL4-3 luc50, 1,300ml of water. Next, 1.5 ml
of 2xHBS (hepes buffer saline) pH 7.0 was added quickly to the tubes and bubbled
for 30 s. HBS/DNA solution was gently dropped onto medium. After 8 h of
incubation at 37 1C with 5% CO2, medium on transfection plates was changed to
10 ml DMEM and once again 1 day after transfection to 7 ml DMEM. Transfection
supernatants were collected after 48 h, centrifuged at 1,200 rpm for 10 min at RT to
remove cell debris, and stored frozen at  80 1C (ref. 51).
Infection of Jurkat cells displaying DC-SIGN in cis. Infection was performed on
Jurkat cells (T-lymphocyte cell line) expressing receptor DC-SIGN on their surface.
One day before infection, 5 104 of Jurkat DC-SIGN cells were plated into each
well of 96-well plate. Cells were incubated at RT for 20 min with the carbohydrate-
based compounds and then challenged with 5000 Tissue Culture Infective Dose of
recombinant viruses. After 48 h of incubation cells were washed twice with PBS and
lysed for luciferase assay. The range of concentrations tested for compounds Qb
and Qb-(Man3)180 was 100 pM–50 nM and for compound Qb-(Man9)180 was
50 pM–50 nM. As a control, an experiment of infection with VSV-G pseudoviruses
was performed under the same conditions. Infection with VSV-G is independent of
the presence of DC-SIGN receptor.
Generation of monocyte-derived DCs (DCs). PBMCs were isolated from buffy
coats from healthy human donors (Hospital 12 de Octubre, Madrid, Spain) by
Ficoll-Paque (Pharmacia, Uppsala, Sweden) density-gradient centrifugation. Fol-
lowing the centrifugation of 40 ml of whole blood samples on Ficoll-Paque at
2,000 rpm for 30 min, the cells from interface were collected and washed five times
with PBS at 1,500 rpm for 5 min at RT. PBMCs were then resuspended in RPMI
medium supplemented with 10% heat-inactivated FBS, 25 mg gentamycin, 2 mM
L-glutamine at concentration 2 106 cells per ml and placed onto 24-well plate for
1 h at 37 1C with 5% CO2. The adherent monolayer of monocytes were then
washed twice with PBS and resuspended in RPMI medium supplemented with
cytokines granulocyte–macrophage colony-stimulating factor (200 ng ml 1) and
IL-4 (10 ng ml 1). For the differentiation of immature monocyte-derived DCs,
cells were incubated at 37 1C with 5% CO2 for 7 days and subsequently activated
with cytokines on day 2 and 5 (refs 44,52,53).
Infection of immature monocyte-derived DCs in cis. Immature monocyte-
derived DCs were incubated at RT for 20 min with the carbohydrate-based com-
pounds and then challenged with 5000 TCID of EBOV-GP recombinant
pseudoviruses. After 48 h of incubation cells were washed twice with PBS and lysed for
luciferase assay. The range of concentrations tested for Qb-(Man9)180 was 1, 5
and 25 nM. As a control, experiment of inhibition of infection of EBOV-GP was
performed in the presence of antibody anti-DC-SIGN and mannan at concentration
of 25mg ml 1.
Statistical methods. Dynamic light scattering: Dynamic light scattering values
represent the average of 10 independent measurements, where 10 individual
acquisitions were taken per measurement the results analysed using OmniSIZE
software.
Infection assays: Statistical analysis was performed using GraphPad Prism v6.0.
Infection of mammalian Jurkat cells displaying DC-SIGN by EboV-GP pseudo-
typed viruses: The values of percentage of infection presented on the graph cor-
respond to the mean of six independent experiments with error bars corresponding
to the s.e.m. The IC50 values were estimated using GraphPad Prism v6.0 with a 95%
confidence interval and settings to normalize dose-response curves.
Infection of primary monocyte-derived DC by EboV-GP pseudotyped viruses: The
values of percentage of infection correspond to the mean of two independent
experiments (error bars describe the range between the two values obtained).
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